Serum visfatin levels and metabolic syndrome criteria in obese female subjects

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 7, 2013, Pages 576-581

  De Luis, D A ^a   Aller, R ^a   Gonzalez Sagrado, M ^a   Conde, R ^a   Izaola, O ^a   De la Fuente, B ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Females; Metabolic syndrome; Obesity; Visfatin

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; FAT MASS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; NUTRITIONAL ASSESSMENT; OBESITY; PREVALENCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

FEMALES; METABOLIC SYNDROME; OBESITY; VISFATIN;

ADULT; BIOLOGICAL MARKERS; BODY WEIGHTS AND MEASURES; CROSS-SECTIONAL STUDIES; CYTOKINES; EATING; FEMALE; FOOD HABITS; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; RISK FACTORS;

EID: 84884970417     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2430     Document Type: Article

References (32)

1. Frayn KN. Subcutaneous and visceral adipose tissue their relation to metabolic syndrome. Endocr Rev 2000; 21: 697-738.
2. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
3. Ognjanovic S. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001; 26: 107-117.
4. Timar O, Sestier F, Levy E. Metabolic syndrome X: a review. Can J Cardiol 2000; 16: 779-789.
5. Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am 2004; 33: 417-429.
6. de Luis DA, Lopez MR, Gonzalez Sagrado M, et al. Prevalence of metabolic syndrome with international diabetes federation criteria and ATP III program in patients 65years of age or older. J Nut Aging 2010; 14: 400-404.
7. Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol 2007; 157(4): 437-442.
8. Malavazos AE, Ermetici F, Cereda E, et al. Epicardial fat thickness. Relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutr Metab Cardiovasc Dis 2008; 18(8): 523-530.
9. Panidis D, Farmakiotis D, Rousso D, et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med 2008; 19(6): 406-412.
10. Sheu WH, Chang TM, Lee WJ, et al. Effect of weight loss on proinflammatory state of mononuclear cells in obese women. Obesity (Silver Spring) 2008; 16(5): 1033-1038.
11. Hallschmid M, Randeva H, Tan BK, Kern W, Lehnert H. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity. 637-640.
12. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism 2007; 56(8): 1131-1134.
13. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007; 30(4): 323-326.
14. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008; 69(6): 878-884.
15. Iacobellis G, Iorio M, Napoli N, et al. Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest 2010; 34(1): e12-e15.
16. Schutte AE, Huisman HW, Schutte R, et al. Adipokines and cardiometabolic function. How are they Interlinked? Regul Pept 2010; 164(2-3): 133-138.
17. Unluturk U, Harmanci A, Yildiz BO, Bayraktar M. Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol (Oxf) 2010; 72(4): 469-474.
18. Krzystek-Korpacka M, Patryn E, Bednarz-Misa I, Hotowy K, Noczynska A. Visfatin in juvenile obesity - the effect of obesity intervention and sex Eur J Clin Invest. 2011; 41(12): 1284-1291.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: ( Adult treatment Panel III ). Jama. 2001; 285(19): 2486-2497.
20. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Df T. Homesotasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-414.
21. Lukaski H, Johson PE. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985; 41(4): 810-817.
22. Mataix J, Mañas M. Tablas de composición de alimentos españoles. Ed: University of Granada, 2003.
23. Hamarstedt A, Pihlajamaki J, ROtter V, et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J CLin Endo Metab 2006; 91: 1181-1184.
24. de Luis DA, Gonzalez Sagrado M, Conde R, ALler R, Izaola O, Romero E. Effect of a hypocaloric dieto n serum visfatin in obese non-diabetic patients. Nutrition 2008; 24: 517-521.
25. Brendt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot specific RNA expresión in humans. Diabetes 2005; 54: 2911-2916.
26. Li RZ, Ma XY, Hu XF, et al. Elevated visfatin levels in obese children are related to proinflammatory factors. J Pediatr Endocrinol Metab 2012; 14: 1-8.
27. Chang YH, Chang DM, Lin KC, Shin S, Lee Y. Visfatin in overweight/obesity, type 2 diabetes mellitas, insulin resistance, metabolic síndrome and cardioavscualr diseases: a meta-analysis and systematic review. Diabetes Metab Res Rev 2011; 27: 515-527.
28. Lin C, Lai M, Li T, et al. Relationship betwen serum retinol binding protein 4 ad visfatin and metabolic syndrome. Diab Res Clin Pract 2009; 85: 24-29.
29. Olszanecka-Glinianowicz M, Kocetak P, Nylec M, Chudek J, Zahorska B. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic síndrome. Arc Med Sci 2012; 2: 214-218.
30. Kocelak P, Chudek J, Olszanecka-Glinianowicz M. Prevalence of metabolic syndrome and insulin resistance in overweight and obese women according to the different diagnostic criteria. Minerva Endocrinol 2012; 37(3): 247-254.
31. Weng JF, Chen J, Hong WC, Luo LF, Yu W, Luo SD. Plasma visfatin, associated with a genetic polymorphism -1535C>T, is correlated with C-reactive protein in Chinese Han patients with traumatic brain injury. Peptides 2012; 40C: 8-12.
32. Olszanecka-Glinianowicz M, Kocelak P, Janowska J, Skorupa A, Nylec M, Zahorska-Markiewicz B. Plasma visfatin and tumor necrosis factor-alpha (TNF-α) levels in metabolic syndrome. Kardiol Pol 2011; 69(8): 802-807.